GlassScriptPhysician profile
Amro El Feki
NPI 1619016631
$11,419.98
in general payments reported to CMS, 2019-2025
60 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $1,426 · 2021: $2,158 · 2022: $2,147 · 2023: $1,991 · 2024: $1,229 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,756.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,208.82 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $1,069.04 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $621.63 | 2019-2025 | Qelbree |
| Amgen INC. | $486.16 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $480.43 | 2019-2023 | Austedo Xr |
| Eisai INC. | $480.27 | 2020-2025 | |
| Lundbeck LLC | $455.33 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $451.50 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $439.95 | 2020-2024 | Spinraza |
| Adamas Pharmaceuticals, INC. | $404.10 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $387.23 | 2020-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $383.63 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $383.24 | 2019-2025 | Nuplazid |
| Abbott Laboratories | $328.32 | 2019-2025 | Infinity, Supera |
| Novartis Pharmaceuticals Corporation | $323.02 | 2019-2024 |
Show all 58 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amro El Feki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.